A Pioneering Approach to Targeted Treatment The quest for effective cancer treatments and vaccines has led to a potentially groundbreaking development: EnGeneIC's Endosomal Disruption Vector (EDV) technology. As a Sydney-based biotech innovator, EnGeneIC has been pushing the boundaries of medical
The rapidly expanding field of biotherapeutic drugs brings with it an imperative need for safety measures that ensure patient protection. One of the most significant challenges inherent in the biotherapeutic industry is the potential for viral contamination, a critical quality concern for health
